Search

Join EHA and BSH and receive a discount on your EHA membership fee!

We are pleased to inform that EHA and the British Society of Haematology (BSH) have joined forces and are offering you the possibility of an EHA-BSH Joint Membership.

Read more

The European Parliament adopts the Regulation on Substances of Human Origins (SoHO)

On April 24, the European Parliament gave its final endorsement to the regulation on Substances of Human Origin (SoHO).

Read more

In Memoriam Anneke Brand

Picture: Ineke Oostveen

 

On Sunday, November 21, 2021, Anneke Brand, MD, PhD, emeritus professor at Leiden University Medical Center (LUMC), passed away suddenly. The European Hematology Association community is deeply saddened by Anneke’s passing.

Read more

Anna Vardi Physician Scientist Research Grant winner 2018

Please tell us more about yourself (name, lab, short bio)
I am Anna Vardi. I am currently working as a Consultant Hematologist at the Hematology Department and HCT Unit, G. Papanikolaou Hospital, Thessaloniki, Greece, under the Directorship of Dr.

Read more

FUNDING ALERT: Calls published on ATMPs, T cells and cancer research

In recent weeks, two Calls for proposals were published that offer relevant funding opportunities for hematologists:

1.

Read more

EHA in EU-funded project on voluntary plasma collection capacity in Europe

EHA to participate in an EU-funded project on “Strengthening voluntary non-remunerated plasma collection capacity in Europe” (SUPPLY)

Context: Plasma shortage 

Plasma-derived medicinal products (PDMPs) are used to treat a variety of rare, chronic, and potentially life-threatening conditions including immune deficiencies, immune-mediated peripheral…

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more